Barclays PLC increased its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 294.2% during ...

EDP-235 is under clinical development by Enanta Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Enanta Pharmaceuticals (ENTA) announced Tuesday it would appeal a recent U.S. federal court ruling that favored Pfizer ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five ...

Technical analysis for Enanta Pharmaceuticals Inc. ENTA including support levels resistance levels and stop losses for ENTA ...

Enanta Pharmaceuticals Inc (ENTA) stock saw a decline, ending the day at $5.75 which represents a decrease of $-0.10 or -1.71% from the prior close of $5.85. The stock opened at $6 and touched a low ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immuno ...

H.C. Wainwright lowered the firm’s price target on Enanta (ENTA) to $18 from $27 and keeps a Buy rating on the shares. Zelicapavir successfully ...

Check the time stamp on this data. Updated AI-Generated Signals for Enanta Pharmaceuticals Inc. (ENTA) available here: ENTA.

Roy Buchanan, an analyst from JMP Securities, reiterated the Buy rating on Enanta Pharmaceuticals (ENTA – Research Report). The associated price target remains the same with $21.00. Pick the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...